🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07258199
Enrolling by invitation Not applicable

TACE Treats Nodular Goiter

NCT07258199 · tracked via the Priya Life Science China tracker
Sponsor
Peking Union Medical College Hospital
Phase
Not applicable
Started
2025-09-01
Last updated
2025-12-02

Condition(s) studied

Nodular Goiter

Investigational drug(s) / intervention(s)

TACE

TACE: TACE, 15,000U bleomycin and 200-400μm drug-loaded microspheres

Study summary

transarterial bleomycin chemoembolization represents a novel minimally invasive therapeutic approach for the management of giant nodular goiter.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical criteria: thyroid enlargement, mostly painless, with compressive symptoms (such as dysphagia, dyspnea) being less common; thyroid function is mostly normal, and a small number may be accompanied by hyperthyroidism or hypothyroidism. * Imaging examinations: ultrasound shows multiple solid or cystic-solid nodules with clear boundaries and no malignant signs such as microcalcification and a vertical-to-horizontal diameter ratio \>1. * Pathological criteria: follicular epithelial cell hyperplasia, no nuclear atypia, and no malignant cellular characteristics (such as mitotic figures, infiltrative growth, etc.). In this study, a thyroid goiter with at least one diameter exceeding 4 cm was considered a giant goiter Exclusion Criteria: * abnormal coagulation profiles; * hepatic or renal impairment; * allergy to contrast media; * refusal of interventional therapy and requirement for surgical treatment or other therapies

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing China

More Peking Union Medical College Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07258199 on ClinicalTrials.gov ↗ ← All trials in China